<?xml version="1.0" encoding="UTF-8"?><CONCLUSION NNC="YES" xmlns:fmx="http://opoce" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://formex.publications.europa.eu/schema/formex-05.55-20141201.xd"><BIB.CONCLUSION><REF.CASE FILE="n.a."><NO.CASE>C‑276/15</NO.CASE></REF.CASE><NO.CELEX>62015CC0276</NO.CELEX><NO.ECLI ECLI="ECLI:EU:C:2016:492">EU:C:2016:492</NO.ECLI><NO.SEQ>0001</NO.SEQ><PAGE.FIRST.ECR>1</PAGE.FIRST.ECR><PAGE.SEQ>1</PAGE.SEQ><PAGE.LAST.ECR>9</PAGE.LAST.ECR><PAGE.TOTAL>9</PAGE.TOTAL></BIB.CONCLUSION><CURR.TITLE><PAGE.HEADER><P>OPINION OF MR SZPUNAR – CASE C‑276/15</P><P>HECHT-PHARMA</P></PAGE.HEADER></CURR.TITLE><TITLE><TI><P><HT TYPE="UC">Opinion of Advocate General</HT></P><P>Szpunar</P><P>delivered on <DATE ISO="20160630">30 June 2016</DATE><NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0001"><P>Original language: English.</P></NOTE></P></TI><STI><P><HT TYPE="BOLD">Case C‑276/15</HT></P><P><HT TYPE="BOLD">Hecht-Pharma GmbH</HT></P><P><HT TYPE="BOLD">v</HT></P><P><HT TYPE="BOLD">Hohenzollern Apotheke, owned by Winfried Ertelt</HT></P><P><HT TYPE="NORMAL">(Request for a preliminary ruling from the Bundesgerichtshof (Federal Court of Justice, Germany))</HT></P></STI></TITLE><INDEX><KEYWORD>Medicinal products for human use</KEYWORD><KEYWORD>Directive 2001/83/EC</KEYWORD><KEYWORD>Scope</KEYWORD><KEYWORD>Articles 2(1) and 3, points 1 and 2</KEYWORD><KEYWORD>Medicinal products prepared industrially or manufactured by a method involving an industrial process</KEYWORD><KEYWORD>Exceptions</KEYWORD><KEYWORD>Medicinal products prepared in a pharmacy in accordance with the prescriptions of a pharmacopoeia</KEYWORD></INDEX><CONTENTS.CONCLUSION><GR.SEQ LEVEL="1"><TITLE><TI><NP><NO.P><HT TYPE="BOLD">I –</HT></NO.P><TXT><HT TYPE="BOLD">Introduction</HT></TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0001"><NO.P>1.</NO.P><TXT>The substance of (frank)incense has intrigued Europe for its spiritual, therapeutic and olfactory properties ever since one of the wise men, Melchior, sourced it from his native Arabia.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0002"><P>Matthew 2, 2-11, referring to the three wise men, writes: <QUOT.START CODE="2018" ID="QS0001" REF.END="QE0001"/>… and when they had opened their treasures, they presented unto him gifts; gold, and frankincense and myrrh.<QUOT.END REF.START="QS0001" CODE="2019" ID="QE0001"/> (King James Version).</P></NOTE> The case at issue in which a German pharmacy produces incense capsules and sells these to local patients is no exception to this, even though its facts are rather more mundane than the quest of the three wise men.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0002"><NO.P>2.</NO.P><TXT>In the present preliminary reference from the Bundesgerichtshof (Federal Court of Justice), the Court is asked whether certain manufacturing activities of a pharmacy fall within or outside the scope of Directive 2001/83/EC<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0003"><P>Directive of the European Parliament and of the Council of <DATE ISO="20011106">6 November 2001</DATE> on the Community code relating to medicinal products for human use (<REF.DOC.OJ COLL="L" NO.OJ="311" PAGE.FIRST="67" DATE.PUB="2001">OJ 2001 L 311, p. 67</REF.DOC.OJ>), as last amended by Directive 2012/26/EU of the European Parliament and of the Council of <DATE ISO="20121025">25 October 2012</DATE> (<REF.DOC.OJ COLL="L" NO.OJ="299" PAGE.FIRST="1" DATE.PUB="2012">OJ 2012 L 299, p. 1</REF.DOC.OJ>).</P></NOTE>. Should the pharmacy’s activity fall within the scope of Directive 2001/83, then a market authorisation would be needed, which is an arduous process that an individual pharmacy cannot possibly undertake successfully. Should it fall outside the scope of the directive, the pharmacy’s product would exist alongside other products, which have been produced on an industrial scale, undergone the authorisation process and are marketed EU-wide.</TXT></NP.ECR></GR.SEQ><?PAGE NO="2"?><GR.SEQ LEVEL="1"><TITLE><TI><NP><NO.P><HT TYPE="BOLD">II –</HT></NO.P><TXT><HT TYPE="BOLD">Legal framework</HT></TXT></NP></TI></TITLE><GR.SEQ LEVEL="2"><TITLE><TI><NP><NO.P>A –</NO.P><TXT><HT TYPE="ITALIC">EU law: Directive 2001/83</HT></TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0003"><NO.P>3.</NO.P><TXT>Article 2(1) of Directive 2001/83 provides:</TXT><P><QUOT.S LEVEL="1"><ALINEA><QUOT.START CODE="2018" ID="QS0002" REF.END="QE0002"/>This Directive shall apply to medicinal products for human use intended to be placed on the market in Member States and either prepared industrially or manufactured by a method involving an industrial process.<QUOT.END REF.START="QS0002" CODE="2019" ID="QE0002"/></ALINEA></QUOT.S></P></NP.ECR><NP.ECR IDENTIFIER="NP0004"><NO.P>4.</NO.P><TXT>Article 3 of Directive 2001/83 is worded as follows:</TXT><P><QUOT.S LEVEL="1"><ALINEA><P><QUOT.START CODE="2018" ID="QS0003" REF.END="QE0003"/>This Directive shall not apply to:</P><LIST TYPE="ARAB"><ITEM><NP><NO.P>1.</NO.P><TXT>Any medicinal product prepared in a pharmacy in accordance with a medical prescription for an individual patient (commonly known as the magistral formula).</TXT></NP></ITEM><ITEM><NP><NO.P>2.</NO.P><TXT>Any medicinal product which is prepared in a pharmacy in accordance with the prescriptions of a pharmacopoeia and is intended to be supplied directly to the patients served by the pharmacy in question (commonly known as the officinal formula).</TXT></NP></ITEM></LIST></ALINEA><P>…<QUOT.END REF.START="QS0003" CODE="2019" ID="QE0003"/></P></QUOT.S></P></NP.ECR><NP.ECR IDENTIFIER="NP0005"><NO.P>5.</NO.P><TXT>According to Article 6(1) of Directive 2001/83</TXT><P><QUOT.S LEVEL="1"><ALINEA><QUOT.START CODE="2018" ID="QS0004" REF.END="QE0004"/>No medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State in accordance with this Directive or an authorisation has been granted in accordance with Regulation (EC) No 726/2004 [of the European Parliament and of the Council of <DATE ISO="20040331">31 March 2004</DATE> laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (<REF.DOC.OJ COLL="L" NO.OJ="136" PAGE.FIRST="1" DATE.PUB="2004">OJ 2004 L 136, p. 1</REF.DOC.OJ>)], read in conjunction with Regulation (EC) No 1901/2006 of the European Parliament and of the Council of <DATE ISO="20061212">12 December 2006</DATE> on medicinal products for paediatric use [<REF.DOC.OJ COLL="L" NO.OJ="378" PAGE.FIRST="1" DATE.PUB="2006">OJ 2006 L 378, p. 1</REF.DOC.OJ>] and Regulation (EC) No 1394/2007 [of the European Parliament and of the Council of <DATE ISO="20071113">13 November 2007</DATE> on advanced therapy medicinal products and amending Directive 2001/83 and Regulation No 726/2004 (<REF.DOC.OJ COLL="L" NO.OJ="324" PAGE.FIRST="121" DATE.PUB="2007">OJ 2007 L 324, p. 121</REF.DOC.OJ>).<QUOT.END REF.START="QS0004" CODE="2019" ID="QE0004"/></ALINEA></QUOT.S></P></NP.ECR><NP.ECR IDENTIFIER="NP0006"><NO.P>6.</NO.P><TXT>Under Article 87(1) of Directive 2001/83:</TXT><P><QUOT.S LEVEL="1"><ALINEA><QUOT.START CODE="2018" ID="QS0005" REF.END="QE0005"/>Member States shall prohibit any advertising of a medicinal product in respect of which a marketing authorisation has not been granted in accordance with Community law.<QUOT.END REF.START="QS0005" CODE="2019" ID="QE0005"/></ALINEA></QUOT.S></P></NP.ECR></GR.SEQ><GR.SEQ LEVEL="2"><TITLE><TI><NP><NO.P>B –</NO.P><TXT><HT TYPE="ITALIC">German law</HT></TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0007"><NO.P>7.</NO.P><TXT>Paragraph 3a of the German Gesetz über die Werbung auf dem Gebiete des Heilwesens (Heilmittelwerbegesetz) (Law on the advertising of medicines: <QUOT.START CODE="2018" ID="QS0006" REF.END="QE0006"/>the HWG<QUOT.END REF.START="QS0006" CODE="2019" ID="QE0006"/>) contains a prohibition on advertising medicinal products that are not authorised. That provision establishes an advertising prohibition only in relation to medicinal products for which authorisation is required. The referring court points out that the advertising prohibition does not apply where the medicinal product does not require authorisation.</TXT></NP.ECR><?PAGE NO="3"?><NP.ECR IDENTIFIER="NP0008"><NO.P>8.</NO.P><TXT>Pursuant to Paragraph 21(2), point 1, of the Arzneimittelgesetz (Law on medicinal products; <QUOT.START CODE="2018" ID="QS0007" REF.END="QE0007"/>AMG<QUOT.END REF.START="QS0007" CODE="2019" ID="QE0007"/>), no authorisation is required for medicinal products that are intended for administration to humans and, on account of the proven frequency with which they are subject of medical and dental prescriptions, the essential manufacturing steps for such products are carried out in a pharmacy as part of the normal pharmacy business producing up to one hundred packages per day ready for dispensation and intended for supply within the framework of the existing pharmacy operating licence.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0004"><P>Such medicinal products are known in German as <QUOT.START CODE="2018" ID="QS0008" REF.END="QE0008"/>Defekturarzneimittel<QUOT.END REF.START="QS0008" CODE="2019" ID="QE0008"/>.</P></NOTE></TXT></NP.ECR></GR.SEQ></GR.SEQ><GR.SEQ LEVEL="1"><TITLE><TI><NP><NO.P><HT TYPE="BOLD">III –</HT></NO.P><TXT><HT TYPE="BOLD">Facts, procedure and questions referred</HT></TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0009"><NO.P>9.</NO.P><TXT>Hecht Pharma GmbH,<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0005"><P>Hereinafter referred to as <QUOT.START CODE="2018" ID="QS0009" REF.END="QE0009"/>Hecht Pharma<QUOT.END REF.START="QS0009" CODE="2019" ID="QE0009"/>.</P></NOTE> the applicant in the main proceedings, sells incense capsules in Germany as a food supplement under the designation <QUOT.START CODE="2018" ID="QS0010" REF.END="QE0010"/>H 15 Weihrauch<QUOT.END REF.START="QS0010" CODE="2019" ID="QE0010"/> (H 15 incense). Mr Ertelt, the defendant in the main proceedings, owns a pharmacy, the Hohenzollern Apotheke where he manufactures incense capsules and sells these, as a medicinal product, under the designation <QUOT.START CODE="2018" ID="QS0011" REF.END="QE0011"/>Weihrauch-Extrakt-Kapseln<QUOT.END REF.START="QS0011" CODE="2019" ID="QE0011"/> (incense extract capsules). He does not have a marketing authorisation for this medicinal product. The parties are agreed that the defendant manufactures the capsules as part of a normal pharmacy business and in compliance with the other requirements of point 1 of Paragraph 21(2) of the AMG.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0010"><NO.P>10.</NO.P><TXT>The defendant promoted his <QUOT.START CODE="2018" ID="QS0012" REF.END="QE0012"/>incense extract capsules<QUOT.END REF.START="QS0012" CODE="2019" ID="QE0012"/> in an <QUOT.START CODE="2018" ID="QS0013" REF.END="QE0013"/>information sheet for patients<QUOT.END REF.START="QS0013" CODE="2019" ID="QE0013"/> and a brochure. The applicant complained that the promotional claims set out in those documents were contrary to (national) competition rules, claiming that these contravened the prohibition on advertising medicinal products that are not authorised. It applied for an injunction to restrain the defendant from promoting in the course of trade his pharmacy’s medicinal product designated <QUOT.START CODE="2018" ID="QS0014" REF.END="QE0014"/>incense extract capsules: 100 capsules<QUOT.END REF.START="QS0014" CODE="2019" ID="QE0014"/> and <QUOT.START CODE="2018" ID="QS0015" REF.END="QE0015"/>incense extract capsules: 200 capsules<QUOT.END REF.START="QS0015" CODE="2019" ID="QE0015"/>.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0011"><NO.P>11.</NO.P><TXT>The defendant contested the action, claiming that the prohibition on advertising medicinal products that are not authorised was not applicable in the present case. In the defendant’s view, that prohibition is linked to the requirement of a marketing authorisation for the medicinal product advertised. However, the <QUOT.START CODE="2018" ID="QS0016" REF.END="QE0016"/>incense extract capsules<QUOT.END REF.START="QS0016" CODE="2019" ID="QE0016"/> he advertised, as a medicinal product falling within the category of <QUOT.START CODE="2018" ID="QS0017" REF.END="QE0017"/>Defekturarzneimittel<QUOT.END REF.START="QS0017" CODE="2019" ID="QE0017"/> in accordance with point 1 of Paragraph 21(2) of the AMG, do not, he contends, require authorisation.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0012"><NO.P>12.</NO.P><TXT>The Landgericht (Regional Court) rejected the action for an injunction. The appellate court dismissed the applicant’s appeal against that judgment. By the present appeal on a point of law (<QUOT.START CODE="2018" ID="QS0018" REF.END="QE0018"/>Revision<QUOT.END REF.START="QS0018" CODE="2019" ID="QE0018"/>), for which leave was granted by the Bundesgerichtshof (Federal Court of Justice), the applicant continues to pursue its claim in full. The defendant argues that the appeal should be dismissed.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0013"><NO.P>13.</NO.P><TXT>The referring court is of the view that the outcome of the appeal depends on whether the <QUOT.START CODE="2018" ID="QS0019" REF.END="QE0019"/>incense extract capsules<QUOT.END REF.START="QS0019" CODE="2019" ID="QE0019"/> medicinal product advertised by the defendant must be authorised under the law on pharmaceutical products. That in turn depends on the interpretation of points 1 and 2 of Article 3 of Directive 2001/83.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0014"><NO.P>14.</NO.P><TXT>It is for this reason that, by order of <DATE ISO="20150416">16 April 2015</DATE>, received by the Court on <DATE ISO="20150609">9 June 2015</DATE>, the Bundesgerichtshof (Federal Court of Justice) referred the following questions for a preliminary ruling:</TXT><P><QUOT.S LEVEL="1"><LIST TYPE="OTHER"><ITEM><NP><NO.P><QUOT.START CODE="2018" ID="QS0020" REF.END="QE0020"/>(1)</NO.P><TXT>Do points 1 and 2 of Article 3 of Directive 2001/83 preclude a national provision such as point 1 of Paragraph 21(2) of the [AMG] according to which no marketing authorisation is required for medicinal products that are intended for administration to humans and, on account of the proven frequency with which they are the subject of medical and dental prescriptions, the essential<?PAGE NO="4"?> manufacturing steps for such products are carried out in a pharmacy as part of the normal pharmacy business producing up to one hundred packages per day ready for dispensation and intended for supply under the existing pharmacy operating licence?</TXT></NP></ITEM></LIST><P>If Question 1 is answered in the affirmative:</P><LIST TYPE="ARAB"><ITEM><NP><NO.P>(2)</NO.P><TXT>Does this conclusion also apply where a national provision such as point 1 of Paragraph 21(2) of the [AMG] is interpreted to mean that no marketing authorisation is required for medicinal products that are intended for administration to humans and, on account of the proven frequency with which they are the subject of medical and dental prescriptions, the essential manufacturing steps for such are carried out in a pharmacy as part of the normal pharmacy business producing up to one hundred packages per day ready for dispensation and intended for supply under the existing pharmacy operating licence, provided that the medicinal product is either supplied to an individual patient in accordance with a medical prescription, not necessarily submitted before the preparation of the medicinal product, or is prepared in the pharmacy in accordance with the prescriptions of a pharmacopoeia and is intended to be supplied directly to patients?<QUOT.END REF.START="QS0020" CODE="2019" ID="QE0020"/></TXT></NP></ITEM></LIST></QUOT.S></P></NP.ECR></GR.SEQ><GR.SEQ LEVEL="1"><TITLE><TI><NP><NO.P><HT TYPE="BOLD">IV –</HT></NO.P><TXT><HT TYPE="BOLD">Analysis</HT></TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0015"><NO.P>15.</NO.P><TXT>By its two questions, which should be examined together, the referring court, in essence, seeks to ascertain whether Article 3, points 1 or 2, of Directive 2001/83 preclude a pharmacy manufacturing medicinal products under the conditions of Paragraph 21(2), point 1, of the AMG.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0016"><NO.P>16.</NO.P><TXT>Despite the fact that it is not apparent from the text of Directive 2001/83 or from systematic or teleological considerations relating to the interpretation of that directive,<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0006"><P>See my Opinion in Joined Cases <REF.DOC.ECR><NAME.CASE><HT TYPE="ITALIC">Abcur</HT></NAME.CASE> (<NO.CASE>C‑544/13 and C‑545/13</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2015:136">EU:C:2015:136</NO.ECLI>, points <REF.NP.ECR REF="NP0023">23</REF.NP.ECR> to <REF.NP.ECR REF="NP0029">29</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE> the Court has now clarified in <HT TYPE="ITALIC">Abcur</HT> that <QUOT.START CODE="2018" ID="QS0021" REF.END="QE0021"/>in order to fall within the scope of Directive 2001/83, the product in question, firstly, must satisfy the conditions laid down in Article 2(1) of that directive and, secondly, must not fall within one of the exceptions expressly provided for in Article 3 of that directive<QUOT.END REF.START="QS0021" CODE="2019" ID="QE0021"/>.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0007"><P>See judgment of <REF.DOC.ECR><DATE ISO="20150716">16 July 2015</DATE> in <NAME.CASE><HT TYPE="ITALIC">Abcur</HT></NAME.CASE> (<NO.CASE>C‑544/13 and C‑545/13</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2015:481">EU:C:2015:481</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0039">39</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0017"><NO.P>17.</NO.P><TXT>As a consequence, just as in <HT TYPE="ITALIC">Abcur</HT>,<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0008"><P>See judgment of <REF.DOC.ECR><DATE ISO="20150716">16 July 2015</DATE> in <NAME.CASE><HT TYPE="ITALIC">Abcur</HT></NAME.CASE> (<NO.CASE>C‑544/13 and C‑545/13</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2015:481">EU:C:2015:481</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0036">36</REF.NP.ECR></REF.DOC.ECR>)</P></NOTE> the questions of the referring court should be extended so as to include Article 2 of Directive 2001/83 in the analysis.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0009"><P>I note, incidentally, that the referring court itself refers to Article 2 of Directive 2001/83 in its order for a preliminary reference.</P></NOTE></TXT></NP.ECR><GR.SEQ LEVEL="2"><TITLE><TI><NP><NO.P>A –</NO.P><TXT><HT TYPE="ITALIC">On Article 2(1) of Directive 2001/83</HT></TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0018"><NO.P>18.</NO.P><TXT>By virtue of Article 2(1) of Directive 2001/83, that directive applies to medicinal products <QUOT.START CODE="2018" ID="QS0022" REF.END="QE0022"/>prepared industrially or manufactured by a method involving an industrial process<QUOT.END REF.START="QS0022" CODE="2019" ID="QE0022"/>.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0019"><NO.P>19.</NO.P><TXT>Directive 2001/83 does not define the concepts of <QUOT.START CODE="2018" ID="QS0023" REF.END="QE0023"/>prepared industrially<QUOT.END REF.START="QS0023" CODE="2019" ID="QE0023"/> and <QUOT.START CODE="2018" ID="QS0024" REF.END="QE0024"/>manufactured by a method involving an industrial process<QUOT.END REF.START="QS0024" CODE="2019" ID="QE0024"/>.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0010"><P>See also judgment of <REF.DOC.ECR><DATE ISO="20150716">16 July 2015</DATE> in <NAME.CASE><HT TYPE="ITALIC">Abcur</HT></NAME.CASE> (<NO.CASE>C‑544/13 and C‑545/13</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2015:481">EU:C:2015:481</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0044">44</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE> The Court has clarified in <HT TYPE="ITALIC">Abcur</HT> that those terms must <QUOT.START CODE="2018" ID="QS0025" REF.END="QE0025"/>include, at the very least, any preparation or manufacture involving an industrial process<QUOT.END REF.START="QS0025" CODE="2019" ID="QE0025"/> and that <QUOT.START CODE="2018" ID="QS0026" REF.END="QE0026"/>such a process is characterised in general by a succession of operations, which may, in particular, be mechanical or chemical, in order to obtain a significant quantify of a standardised product<QUOT.END REF.START="QS0026" CODE="2019" ID="QE0026"/>.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0011"><P>See judgment of <REF.DOC.ECR><DATE ISO="20150716">16 July 2015</DATE> in <NAME.CASE><HT TYPE="ITALIC">Abcur</HT></NAME.CASE> (<NO.CASE>C‑544/13 and C‑545/13</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2015:481">EU:C:2015:481</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0050">50</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE><?PAGE NO="5"?> Accordingly, the Court found that <QUOT.START CODE="2018" ID="QS0027" REF.END="QE0027"/>the standardised production of significant quantities of a medicinal product to be stocked and sold wholesale and the large-scale or serial production of magistral formulae in batches [were] characteristic of industrial preparation or manufacture by a method involving an industrial process<QUOT.END REF.START="QS0027" CODE="2019" ID="QE0027"/>.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0012"><P>See judgment of <REF.DOC.ECR><DATE ISO="20150716">16 July 2015</DATE> in <NAME.CASE><HT TYPE="ITALIC">Abcur</HT></NAME.CASE> (<NO.CASE>C‑544/13 and C‑545/13</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2015:481">EU:C:2015:481</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0051">51</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0020"><NO.P>20.</NO.P><TXT>In <HT TYPE="ITALIC">Abcur</HT>, a pharmaceutical laboratory produced medicinal products on a large scale. Consequently, the Court held that the products in question fell within the scope of Article 2 of Directive 2001/83.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0013"><P>Judgment of <REF.DOC.ECR><DATE ISO="20150716">16 July 2015</DATE> in <NAME.CASE><HT TYPE="ITALIC">Abcur</HT></NAME.CASE> (<NO.CASE>C‑544/13 and C‑545/13</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2015:481">EU:C:2015:481</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0052">52</REF.NP.ECR></REF.DOC.ECR>). Needless to add that the Court specified, as it tends to do, that this was a question of fact, the establishment of which ultimately fell to the referring court.</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0021"><NO.P>21.</NO.P><TXT>By contrast, I would submit that the circumstances of the case in the main proceedings are clearly distinct from those in <HT TYPE="ITALIC">Abcur</HT> and that, in casu, we are not dealing with medicinal products <QUOT.START CODE="2018" ID="QS0028" REF.END="QE0028"/>prepared industrially or manufactured by a method involving an industrial process<QUOT.END REF.START="QS0028" CODE="2019" ID="QE0028"/>.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0022"><NO.P>22.</NO.P><TXT>First, as the German Government points out, the products in question are essentially the result of an exercise of individual craftsmanship, which is not akin to <QUOT.START CODE="2018" ID="QS0029" REF.END="QE0029"/>standardised production<QUOT.END REF.START="QS0029" CODE="2019" ID="QE0029"/> and which is, moreover, subject to strict protocol requirements.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0014"><P>See Paragraph 8(1) and (2) of the Verordnung über den Betrieb von Apotheken (Apothekenbetriebsordnung) (Regulation on the operation of pharmacies: <QUOT.START CODE="2018" ID="QS0030" REF.END="QE0030"/>the ApBetrO<QUOT.END REF.START="QS0030" CODE="2019" ID="QE0030"/>).</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0023"><NO.P>23.</NO.P><TXT>Secondly, German law<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0015"><P>Paragraph 21(2), point 1, of the AMG.</P></NOTE> limits production to 100 packages per day ready for dispensation. This is, in my view, no ‘significant quantity’. In any event, this upper limit will rarely be attained, as the case at issue demonstrates. According to Hohenzollern Apotheke, in 2015 merely 213 packages were dispensed. A pharmacy selling this number of packages will, typically, not produce far more than that.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0024"><NO.P>24.</NO.P><TXT>Thirdly, the fact that the manufacturing has to occur in the context of the regular running of the pharmacy points to the fact that it is limited in scope. It should not be forgotten that a pharmacy principally sells products manufactured elsewhere.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0025"><NO.P>25.</NO.P><TXT>I do not, therefore, see the requirements of Article 2 of Directive 2001/83 as being fulfilled. Ergo, the medicinal products in question do not fall within the scope of the directive.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0026"><NO.P>26.</NO.P><TXT>In my view, the case should end here and the referring court should be told that Directive 2001/83, in particular Article 2 thereof, does not preclude a pharmacy manufacturing medicinal products under the conditions of Paragraph 21(2), point 1, of the AMG.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0027"><NO.P>27.</NO.P><TXT>Should the Court, however, be of the opinion that the requirements of Article 2 of Directive 2001/83 are fulfilled, then Article 3 of that directive needs to be examined. What follows is, therefore, offered on this hypothetical basis only.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0028"><NO.P>28.</NO.P><TXT>Article 3 contains a number of exceptions to the applicability of the directive. The referring court is unclear as to whether points 1 or 2 of Article 3 of the directive are relevant for the case at issue.</TXT></NP.ECR></GR.SEQ><?PAGE NO="6"?><GR.SEQ LEVEL="2"><TITLE><TI><NP><NO.P>B –</NO.P><TXT><HT TYPE="ITALIC">On Article 3, point 1, of Directive 2001/83</HT></TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0029"><NO.P>29.</NO.P><TXT>Pursuant to Article 3, point 1, of Directive 2001/83, the directive is not to apply to any medicinal product prepared in a pharmacy in accordance with a medical prescription for an individual patient (commonly known as the magistral formula). Those conditions are cumulative, so that the exception provided for in Article 3, point 1, of Directive 2001/83 cannot apply if one of them is not satisfied.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0016"><P>See judgment of <REF.DOC.ECR><DATE ISO="20150716">16 July 2015</DATE> in <NAME.CASE><HT TYPE="ITALIC">Abcur</HT></NAME.CASE> (<NO.CASE>C‑544/13 and C‑545/13</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2015:481">EU:C:2015:481</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0059">59</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE> By virtue of Article 1(19) of Directive 2001/83, a <QUOT.START CODE="2018" ID="QS0031" REF.END="QE0031"/>medical prescription<QUOT.END REF.START="QS0031" CODE="2019" ID="QE0031"/> is issued by a professional person qualified to do so.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0030"><NO.P>30.</NO.P><TXT>Given the lack of such medical prescription and the unambiguous wording of Article 3, point 1, of Directive 2001/83, I would assume that this provision is not applicable in the case at issue. In this connection, I do note that neither Ireland or Finland considers that Article 3, point 1, requires the preparation of magistral formula only after a clinician has drawn up a prescription for an individual patient. However, as I have argued previously, I find the wording of Article 3, point 1, sufficiently clear to imply that a patient must be identified before the medicinal product is produced.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0017"><P>See my Opinion in Joined Cases <REF.DOC.ECR><NAME.CASE><HT TYPE="ITALIC">Abcur</HT></NAME.CASE> (<NO.CASE>C‑544/13 and C‑545/13</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2015:136">EU:C:2015:136</NO.ECLI>, point <REF.NP.ECR REF="NP0047">47</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0031"><NO.P>31.</NO.P><TXT>Article 3, point 1, of Directive 2001/83 is, therefore, not applicable to the case at issue.</TXT></NP.ECR></GR.SEQ><GR.SEQ LEVEL="2"><TITLE><TI><NP><NO.P>C –</NO.P><TXT><HT TYPE="ITALIC">On Article 3, point 2, of Directive 201/83</HT></TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0032"><NO.P>32.</NO.P><TXT>Let us, therefore, turn to Article 3, point 2, of Directive 2001/83.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0033"><NO.P>33.</NO.P><TXT>According to this provision, the directive is not to apply to any medicinal product which is prepared in a pharmacy in accordance with the prescriptions of a pharmacopoeia and is intended to be supplied directly to the patients served by the pharmacy in question (commonly known as the officinal formula). Those conditions are also cumulative so that the exception provided for in that provision cannot be applied if one of them is not satisfied.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0018"><P>See judgment of <REF.DOC.ECR><DATE ISO="20150716">16 July 2015</DATE> in <NAME.CASE><HT TYPE="ITALIC">Abcur</HT></NAME.CASE> (<NO.CASE>C‑544/13 and C‑545/13</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2015:481">EU:C:2015:481</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0066">66</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0034"><NO.P>34.</NO.P><TXT>The only requirement which merits closer examination is that of <QUOT.START CODE="2018" ID="QS0032" REF.END="QE0032"/>in accordance with the prescriptions of a pharmacopeia<QUOT.END REF.START="QS0032" CODE="2019" ID="QE0032"/>, for the other requirements of Article 3, point 2, are, in my view, clearly fulfilled.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0035"><NO.P>35.</NO.P><TXT>The referring court is uncertain as to whether point 1 of Paragraph 21(2) of the AMG is compatible with EU law because the German provision does not require the medicinal product manufactured in a pharmacy to be prepared in accordance with a pharmacopoeia.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0036"><NO.P>36.</NO.P><TXT>Yet, the German Government stresses that pursuant to Paragraph 21(2), point 1, of the AMG, manufacturing must take place within the framework of the existing pharmacy operating licence. In addition, while Paragraph 21(2), point 1, of the AMG does not require such medicinal products to be prepared in accordance with the requirements of a pharmacopoeia, Paragraph 6(1) of the ApBetrO specifies the following: medicinal products produced in a pharmacy must be produced in accordance with the quality of pharmaceutical science<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0019"><P>See Paragraph 1 of the provision.</P></NOTE> and must be manufactured and checked according to recognised pharmaceutical rules, and if the pharmacopoeia contains rules, such rules have to be complied with.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0020"><P>See Paragraph 2 of the provision.</P></NOTE> Paragraph 55 of the AMG in turn stipulates that <QUOT.START CODE="2018" ID="QS0033" REF.END="QE0033"/>the Pharmacopoeia is a collection<?PAGE NO="7"?> of recognised pharmaceutical rules regarding the quality, testing, storage, dispensing and designation of medicinal products and the substances used in their manufacture, published by the Federal Institute for Drugs and Medical Devices in agreement with the Paul Ehrlich Institute and the Federal Agency for Consumer Protection and Food Safety<QUOT.END REF.START="QS0033" CODE="2019" ID="QE0033"/>.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0021"><P>See Paragraph 55(1), first sentence, of the AMG, in the form of the translation provided by the Language Service of the German Federal Ministry of Health, available at: https://www.gesetze-im-internet.de/englisch_amg/englisch_amg.html#p1223.</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0037"><NO.P>37.</NO.P><TXT>Moreover, as the German Government correctly points out, the term <QUOT.START CODE="2018" ID="QS0034" REF.END="QE0034"/>pharmacopoeia<QUOT.END REF.START="QS0034" CODE="2019" ID="QE0034"/> is neither defined in Directive 2001/83 nor in other acts of secondary law. Nor, has it been, to my knowledge, defined by the Court. A pharmacopoeia (etymologically, <QUOT.START CODE="2018" ID="QS0035" REF.END="QE0035"/>drug-making<QUOT.END REF.START="QS0035" CODE="2019" ID="QE0035"/>), in its modern technical sense, is, as is also reflected in the abovementioned Paragraph 55 of the AMG, a book containing directions for the identification of compound medicines, and published by the authority of a government or a medical or pharmaceutical society.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0022"><P>See https://en.wikipedia.org/wiki/Pharmacopoeia.</P></NOTE> The most prominent one in Europe, which is also repeatedly referred to in the context of Directive 2001/83 is the European Pharmacopeia, administered by the European Directorate for the Quality of Medicines and Healthcare (EDQM), a directorate of the Council of Europe in Strasbourg.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0023"><P>See https://www.edqm.eu/.</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0038"><NO.P>38.</NO.P><TXT>As regards the case at issue, Hohenzollern Apotheke stresses that there are relevant rules contained, inter alia, in the Council of Europe’s European Pharmacopoeia which it complies with in the manufacturing of its incense capsules. Therefore, the requirements of Article 3, point 2, of Directive 2001/83 are complied with as far as the activities at issue of Hohenzollern Apotheke are concerned.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0039"><NO.P>39.</NO.P><TXT>As regards the wider question whether the cited German provisions also comply with Article 3, point 2, in general, I should like to stress the following: given that since <HT TYPE="ITALIC">Abcur</HT> the Court seems to assume that Article 3, point 2, of Directive 2001/83 applies to medicinal products fulfilling the requirements of Article 2 of that directive (<QUOT.START CODE="2018" ID="QS0036" REF.END="QE0036"/>prepared industrially or manufactured by a method involving an industrial process<QUOT.END REF.START="QS0036" CODE="2019" ID="QE0036"/>),<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0024"><P>See point 17 of this Opinion and judgment of <REF.DOC.ECR><DATE ISO="20150716">16 July 2015</DATE> in <NAME.CASE><HT TYPE="ITALIC">Abcur</HT></NAME.CASE> (<NO.CASE>C‑544/13 and C‑545/13</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2015:481">EU:C:2015:481</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0039">39</REF.NP.ECR></REF.DOC.ECR>). As is known, I think matters are less straightforward than that, see my Opinion in Joined Cases <REF.DOC.ECR><NAME.CASE><HT TYPE="ITALIC">Abcur</HT></NAME.CASE> (<NO.CASE>C‑544/13 and C‑545/13</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2015:136">EU:C:2015:136</NO.ECLI>, points <REF.NP.ECR REF="NP0023">23</REF.NP.ECR> to <REF.NP.ECR REF="NP0029">29</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE> then the requirement of the <QUOT.START CODE="2018" ID="QS0037" REF.END="QE0037"/>prescriptions of a pharmacopoeia<QUOT.END REF.START="QS0037" CODE="2019" ID="QE0037"/> should be interpreted strictly in accordance with its literal meaning, in particular as Article 3 of Directive 2001/83 is an exception to a general rule.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0025"><P>See judgment of <REF.DOC.ECR><DATE ISO="20150716">16 July 2015</DATE> in <NAME.CASE><HT TYPE="ITALIC">Abcur</HT></NAME.CASE> (<NO.CASE>C‑544/13 and C‑545/13</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2015:481">EU:C:2015:481</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0054">54</REF.NP.ECR></REF.DOC.ECR> and the case-law cited).</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0040"><NO.P>40.</NO.P><TXT>Therefore, the wording <QUOT.START CODE="2018" ID="QS0038" REF.END="QE0038"/>in accordance with the prescriptions of a pharmacopoeia<QUOT.END REF.START="QS0038" CODE="2019" ID="QE0038"/> implies that if such prescriptions exist they imperatively need to be followed. If they do not exist, I would have difficulty in accepting that this requirement for products that are <QUOT.START CODE="2018" ID="QS0039" REF.END="QE0039"/>prepared industrially or manufactured by a method involving an industrial process<QUOT.END REF.START="QS0039" CODE="2019" ID="QE0039"/> to be excepted from the directive, under Article 3, can be simply dispensed with.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0041"><NO.P>41.</NO.P><TXT>It will be for the referring court to interpret the German provisions in light of this finding. The requirement of following the prescriptions of a pharmacopoeia cannot, however, be disregarded in the context of such interpretation.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0042"><NO.P>42.</NO.P><TXT>Moreover, such an interpretation is fully in line with the overarching objective of Directive 2001/83, which is the protection of public health.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0026"><P>See recital 2 of the directive.</P></NOTE> The German provisions have within them sufficient safeguards to protect that public health objective. Finally, the medicinal products in question are to be supplied directly to patients. Such local and direct supplies do not interfere with the internal market logic underpinning the directive.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0027"><P>See recital 3 of the directive.</P></NOTE></TXT></NP.ECR><?PAGE NO="8"?><NP.ECR IDENTIFIER="NP0043"><NO.P>43.</NO.P><TXT>In conclusion, Article 3, point 2, of Directive 2001/83 does not preclude a pharmacy manufacturing medicinal products under the conditions of Paragraph 21(2), point 1, of the AMG.</TXT></NP.ECR></GR.SEQ><GR.SEQ LEVEL="2"><TITLE><TI><NP><NO.P>D –</NO.P><TXT><HT TYPE="ITALIC">On advertising</HT></TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0044"><NO.P>44.</NO.P><TXT>The referring court is, in my view, correct in assuming that the provisions of Directive 2001/83 concerning the requirement of a marketing authorisation pursuant to Article 6(1) of the directive and the advertising prohibition pursuant to Article 87(1) of the directive apply only to medicinal products that satisfy the requirements of Article 2(1) of the directive and are not excepted from the scope of the directive by Article 3 of the directive.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0045"><NO.P>45.</NO.P><TXT>Article 87(1) of Directive 2001/83, by virtue of which Member States are to prohibit any advertising of a medicinal product in respect of which a marketing authorisation has not been granted in accordance with Union law is immaterial to the case at issue, for it does not apply to medicinal products falling outside the scope of Directive 2001/83. In <HT TYPE="ITALIC">Ludwigs-Apotheke</HT>, the Court held that medicinal products covered by a provision of the AMG were excluded from the scope of Directive 2001/83 and that, accordingly, the provisions of Title VIII, on advertising, of that directive were not applicable to them.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0028"><P>See judgment of <REF.DOC.ECR><DATE ISO="20071108">8 November 2007</DATE> in <NAME.CASE><HT TYPE="ITALIC">Ludwigs-Apotheke</HT></NAME.CASE> (<NO.CASE>C‑143/06</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2007:656">EU:C:2007:656</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0023">23</REF.NP.ECR></REF.DOC.ECR>). See also my Opinion in Joined Cases <REF.DOC.ECR><NAME.CASE><HT TYPE="ITALIC">Abcur</HT></NAME.CASE> (<NO.CASE>C‑544/13 and C‑545/13</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2015:136">EU:C:2015:136</NO.ECLI>, point <REF.NP.ECR REF="NP0078">78</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0046"><NO.P>46.</NO.P><TXT>This finding is without prejudice to other possible restrictions stemming from EU law. In this context, I should, in particular like to stress that, in a situation, such as in the case at issue, where Directive 2001/83 is not applicable, the (general) Directive 2006/114/EC<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0029"><P>Directive of the European Parliament and of the Council of <DATE ISO="20061212">12 December 2006</DATE> concerning misleading and comparative advertising (codified version) (<REF.DOC.OJ COLL="L" NO.OJ="376" PAGE.FIRST="21" DATE.PUB="2006">OJ 2006 L 376, p. 21</REF.DOC.OJ>).</P></NOTE> is still applicable.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0030"><P>See my Opinion in Joined Cases <REF.DOC.ECR><NAME.CASE><HT TYPE="ITALIC">Abcur</HT></NAME.CASE> (<NO.CASE>C‑544/13 and C‑545/13</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2015:136">EU:C:2015:136</NO.ECLI>, points <REF.NP.ECR REF="NP0075">75</REF.NP.ECR> to <REF.NP.ECR REF="NP0083">83</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE></TXT></NP.ECR></GR.SEQ></GR.SEQ><GR.SEQ LEVEL="1"><TITLE><TI><NP><NO.P><HT TYPE="BOLD">V –</HT></NO.P><TXT><HT TYPE="BOLD">Conclusion</HT></TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0047"><NO.P>47.</NO.P><TXT>In the light of the above considerations I propose that the Court should answer the questions of the Bundesgerichtshof (Federal Court of Justice) as follows:</TXT><P><LIST TYPE="ARAB"><ITEM><NP><NO.P>(1)</NO.P><TXT>Article 2(1) of Directive 2001/83/EC of the European Parliament and of the Council of <DATE ISO="20011106">6 November 2001</DATE> on the Community code relating to medicinal products for human use, as last amended by Directive 2012/26/EU of the European Parliament and of the Council of <DATE ISO="20121025">25 October 2012</DATE>, does not preclude a national law such as Article 21(2), point 1, of the Arzneimittelgesetz (Law on medicinal products), according to which no marketing authorisation is required for medicinal products that are intended for administration to humans and, on account of the proven frequency with which they are the subject of medical and dental prescriptions, the essential manufacturing steps for such products are carried out in a pharmacy as part of the normal pharmacy business producing up to one hundred packages per day ready for dispensation and intended for supply under the existing pharmacy operating licence.</TXT></NP></ITEM><ITEM><NP><NO.P>(2)</NO.P><TXT>Should the Court not follow the interpretation proposed under the previous point and consider the requirements of Article 2(1) of Directive 2001/83 to be fulfilled, then Article 3, point 2, of Directive 2001/83 does not preclude a national law such as Article 21(2), point 1, of the Arzneimittelgesetz (Law on medicinal products), according to which no marketing authorisation is required for medicinal products that are intended for administration to humans and, on account of the proven frequency with which they are the subject of medical and dental prescriptions, the essential manufacturing steps for such products are carried out in a pharmacy<?PAGE NO="9"?> as part of the normal pharmacy business producing up to one hundred packages per day ready for dispensation and intended for supply under the existing pharmacy operating licence, provided that the prescriptions of a pharmacopoeia are complied with.</TXT></NP></ITEM></LIST></P></NP.ECR></GR.SEQ></CONTENTS.CONCLUSION></CONCLUSION>